Candriam S.C.A. raised its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 59.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 215,421 shares of the company's stock after purchasing an additional 80,421 shares during the quarter. Candriam S.C.A. owned 0.38% of Structure Therapeutics worth $5,842,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP raised its holdings in Structure Therapeutics by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company's stock valued at $341,015,000 after buying an additional 221,851 shares during the last quarter. FMR LLC raised its stake in shares of Structure Therapeutics by 6.7% during the third quarter. FMR LLC now owns 6,128,444 shares of the company's stock valued at $268,977,000 after acquiring an additional 383,635 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company's stock worth $173,623,000 after purchasing an additional 602,609 shares during the period. Point72 Asset Management L.P. grew its stake in shares of Structure Therapeutics by 196.5% in the third quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company's stock worth $54,348,000 after purchasing an additional 820,589 shares during the last quarter. Finally, Vestal Point Capital LP increased its holdings in Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company's stock valued at $50,474,000 after purchasing an additional 590,000 shares during the period. Hedge funds and other institutional investors own 91.78% of the company's stock.
Structure Therapeutics Trading Up 4.3 %
GPCR stock traded up $0.89 during midday trading on Wednesday, hitting $21.42. The company's stock had a trading volume of 1,568,941 shares, compared to its average volume of 833,009. The company has a market cap of $1.23 billion, a PE ratio of -28.95 and a beta of -2.35. The firm's 50-day moving average is $25.72 and its 200-day moving average is $32.74. Structure Therapeutics Inc. has a 12 month low of $19.39 and a 12 month high of $62.74.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research analysts have commented on the stock. William Blair assumed coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating for the company. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price target on the stock. JMP Securities restated a "market outperform" rating and issued a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $81.29.
Check Out Our Latest Research Report on Structure Therapeutics
About Structure Therapeutics
(
Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Articles
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
